Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics.
Bacterial endotoxin [e.g. lipopolysaccharide (LPS)] can trigger systemic hyper-inflammatory that subsequently leads to multiple organ failure and lethality (gram-negative sepsis). This paper describes the development of endotoxin-neutralizing peptides that potentially treat sepsis. These peptides have been derived from bactericidal/permeability-increasing protein (BPIP), anti-microbial peptides, and leukocyte CD18 antigen and some of these peptides have been tested in clinical studies.
Department of Surgery, The University of Hong Kong, Jockey Club Clinical Research Center, 21 Sassoon Road, Pokfulam, Hong Kong. tonywkf@hku.hk
Kwong-Fai
KF
Wong
John M
JM
Luk
D000595:Amino Acid Sequence; D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D018821:CD18 Antigens / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D004731:Endotoxins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006090:Gram-Negative Bacteria / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy*
D023181:Antimicrobial Cationic Peptides; D018821:CD18 Antigens; D004731:Endotoxins; D010455:Peptides